Sign in Subscribe

Archive

A collection of 715 issues

Latest

Traditional Risk Factors Not Linked to Early-Onset CRC Rise

Skip to content The CRC Digest Traditional Risk Factors Not Linked to Early-Onset CRC Rise A national cohort study using the All of Us Research Program found no significant association between traditional environmental risk factors or established genetic variants and the rising incidence of colorectal cancer in adults under age

FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC A multicenter trial tested modified FOLFOXIRI combined with panitumumab every two weeks in patients with left-sided, RAS wild-type metastatic colorectal cancer. (The Oncologist) This content is informational only and does not

Follow-Up Colonoscopy Completion After Positive Stool DNA Test in Community Practice

Skip to content The CRC Digest ▪ SCREENING Follow-Up Colonoscopy Completion After Positive Stool DNA Test in Community Practice In a real-world study of patients with positive multi-target stool DNA tests, researchers evaluated follow-up colonoscopy completion rates and advanced neoplasia findings within 365 days. (Current Medical Research and Opinion) This content

WNT Pathway Activation Drives Immune Evasion in BRAF-Mutant Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH WNT Pathway Activation Drives Immune Evasion in BRAF-Mutant Colorectal Cancer Researchers using mouse models and organoids found that WNT pathway activation promotes malignant transformation and immune evasion in microsatellite-stable BRAF-mutant colorectal cancer. (Gastroenterology) This content is informational only and does not constitute medical

BREAKWATER Cohort 3: Encorafenib, Cetuximab, and FOLFIRI Tested in BRAF V600E-Mutant CRC

Skip to content The CRC Digest ◆ TRIAL DATA BREAKWATER Cohort 3: Encorafenib, Cetuximab, and FOLFIRI Tested in BRAF V600E-Mutant CRC A randomized study compared encorafenib plus cetuximab and FOLFIRI against FOLFIRI with or without bevacizumab in patients with BRAF V600E-mutant colorectal cancer. (Annals of Oncology) This content is informational only

CRC Research Update — August 18, 2026

Today's colorectal cancer research highlights

Low Cancer Risk After Negative Colonoscopy Following Positive Stool DNA Test

Skip to content The CRC Digest Low Cancer Risk After Negative Colonoscopy Following Positive Stool DNA Test Community practice data show that patients with a positive multitarget stool DNA test but negative colonoscopy had low rates of subsequent aerodigestive cancers. (Clinical and Translational Gastroenterology) This content is informational only and

FIT Performance Evaluated for Screening Younger Adults

Skip to content The CRC Digest FIT Performance Evaluated for Screening Younger Adults A multicutoff analysis examined how fecal immunochemical testing performs for colorectal cancer screening in people under 50. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist or care

Toxicity Comparison Tool Helps Patients Choose Between Fruquintinib and Regorafenib

Skip to content The CRC Digest ♥ LIVING WITH CRC Toxicity Comparison Tool Helps Patients Choose Between Fruquintinib and Regorafenib Researchers developed a weighted toxicity score to help patients and clinicians compare side effects between two later-line treatment options, supporting more informed treatment decisions in metastatic colorectal cancer. (Clinical Colorectal Cancer)

DPD Enzyme Pathway May Predict Immunotherapy Response in MSI-H CRC

Skip to content The CRC Digest ◇ RESEARCH DPD Enzyme Pathway May Predict Immunotherapy Response in MSI-H CRC A new study identifies the dihydropyrimidine dehydrogenase (DPD) metabolic pathway as the first predictor of immune checkpoint inhibitor efficacy in MSI-H tumors, potentially helping identify patients at risk for resistance. (Journal for ImmunoTherapy